BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech)
Drug Alias NameLCAR-BCX cellsLCAR-BCX
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein inhibitors
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Legend Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Legend Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A